Pharmion (PHRM) shot up 65% on the FDA approval of Vidaza last Thursday, closing at 39.91. (See Pharmion Surges on Drug Approval.) It has settled back to around 37, still a 50% rise from pricing prior to the news. So did you miss this one? We, and apparently Morgan Stanley, don’t think so.
